BiotechTube
MediBeacon

MediBeacon

Munich, Germany· Est.
medibeacon.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $21.8M

Overview

MediBeacon is a private medical device and diagnostics company that has developed a proprietary platform combining fluorescent tracer agents with transdermal sensor technology for non-invasive physiological monitoring. The company achieved a significant milestone with FDA Premarket Approval (PMA) for its Transdermal GFR System, a point-of-care solution for measuring kidney function. Beyond nephrology, MediBeacon is expanding its platform into preclinical research and clinical development for applications in gastroenterology, ophthalmology, and surgery, targeting multiple unmet medical needs with its fluorescence-based technology.

NephrologyGastroenterologyOphthalmologySurgery

Technology Platform

Proprietary platform combining engineered fluorescent tracer agents with transdermal optical sensor technology for non-invasive, real-time physiological monitoring.

Funding History

2
Total raised:$21.8M
Grant$1.8M
Series B$20M

Opportunities

The FDA approval for its Transdermal GFR System provides a beachhead in the large chronic kidney disease management market.
The adaptable platform allows for expansion into other high-value diagnostic areas like gastroenterology and ophthalmology, each representing multi-billion dollar opportunities.
The preclinical research tools segment offers an ongoing revenue stream and de-risks new clinical applications through external validation.

Risk Factors

Key risks include commercial execution challenges in launching a novel diagnostic, securing adequate reimbursement, and displacing entrenched standard-of-care tests.
The platform's expansion into new indications carries clinical development and regulatory risks.
The company also faces competition from other non-invasive monitoring technologies and must maintain rigorous quality and regulatory compliance as a global medtech firm.

Competitive Landscape

In nephrology, MediBeacon competes with standard serum creatinine/eGFR tests and more accurate but invasive plasma clearance methods (e.g., iohexol). Its non-invasive, real-time offering is differentiated. In broader sensing, it may face competition from other optical sensing startups and established diagnostic companies developing point-of-care devices. Its platform's specificity (fluorescent agent + dedicated sensor) creates a potential barrier to entry.

More companies in Diagnostics & Precision Medicine →More companies in Germany →